Like most websites The Pathologist uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Subscribe to Newsletter
Subspecialties Endocrinology, Biochemistry and molecular biology, Neurology, Screening and monitoring

Demystifying Diabetic Neuropathy

In some communities, nearly half of all people with type 2 diabetes will develop nerve damage and peripheral neuropathy (1). And although medications and therapies can mitigate symptoms, the underlying factors that trigger the development of neuropathy are not yet fully understood. Notably, current treatments cannot effectively prevent peripheral neuropathy; even good blood glucose control only partially prevents its onset (2). But what if predictive – and modifiable – metabolic factors existed?

A recent study has discovered a link between a number of specific lipid biomarkers and the development of neuropathy in people with type 2 diabetes (3). The retrospective study used mass spectrometry to analyze 10-year-old serum samples from 69 patients with type 2 diabetes. For each participant, the researchers generated a serum lipidomic profile featuring 435 lipid species from 18 classes. The team noticed a pattern in the lipidomic profiles of those who went on to develop neuropathy – as identified by the Michigan Neuropathy Screening Instrument (MNSI) examination – compared with those who did not. Specifically, participants with a high MNSI index had significantly decreased medium-chain acylcarnitines, increased total free fatty acids, decreased phosphatidylcholines, and increased lysophosphatidylcholines.

The authors noted that neuropathy did not seem to affect the abundance of other lipid classes. They also indicated that the overall findings indicate that lipid changes may be related to impaired mitochondrial β-oxidation, which is notable because it suggests that conventional medications for lowering lipid levels may not effectively treat neuropathy.

Receive content, products, events as well as relevant industry updates from The Pathologist and its sponsors.
Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

  1. CW Hicks, E Selvin, “Epidemiology of peripheral neuropathy and lower extremity disease in diabetes,” Curr Diab Rep, 19, 86 (2019). PMID: 31456118.
  2. BC Callaghan et al., “Enhanced glucose control for preventing and treating diabetic neuropathy,” Cochrane Database Syst Rev, 13, (2012). PMID: 22696371.
  3. F Afshinnia et al., “Serum lipidomic determinants of human diabetic neuropathy in type 2 diabetes,” Ann Clin Transl Neurol, 9, 1392 (2022). PMID: 35923113.
About the Author
George Francis Lee

Associate Editor, The Pathologist

Like most people, I didn’t know exactly what I wanted to do after university. But one thing was certain – writing would play a central role. Not one to walk the path most traveled, I decided to spend my next few years freelancing to hone my skills as a writer and further cement my love for language. Reaching people through writing is important to me and I look forward to connecting with thousands of people through Texere’s passionate audience.

Register to The Pathologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Pathologist magazine